GoodRx (NASDAQ:GDRX) Price Target Cut to $8.50 by Analysts at UBS Group

GoodRx (NASDAQ:GDRX) had its price objective lowered by UBS Group from $9.00 to $8.50 in a research note published on Friday, Benzinga reports. UBS Group currently has a neutral rating on the stock.

Several other research analysts have also commented on GDRX. Raymond James upgraded shares of GoodRx from an outperform rating to a strong-buy rating and set a $10.00 price target on the stock in a research note on Friday. TD Cowen raised their target price on GoodRx from $14.00 to $16.00 and gave the company a buy rating in a report on Thursday, May 16th. Morgan Stanley upped their price target on GoodRx from $7.00 to $9.50 and gave the stock an equal weight rating in a research note on Monday, June 10th. Barclays increased their price objective on GoodRx from $9.00 to $10.00 and gave the company an overweight rating in a report on Monday, May 20th. Finally, Royal Bank of Canada upgraded GoodRx from a sector perform rating to an outperform rating and boosted their target price for the stock from $8.00 to $10.00 in a report on Thursday, May 23rd. One research analyst has rated the stock with a sell rating, four have assigned a hold rating, nine have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of Moderate Buy and an average target price of $9.36.

GoodRx Stock Up 2.9 %

GDRX stock traded up $0.20 during mid-day trading on Friday, hitting $7.21. The stock had a trading volume of 3,233,761 shares, compared to its average volume of 1,471,224. GoodRx has a 1-year low of $4.14 and a 1-year high of $9.26. The company has a fifty day moving average of $8.27 and a 200 day moving average of $7.38. The company has a current ratio of 6.29, a quick ratio of 6.29 and a debt-to-equity ratio of 1.02. The stock has a market capitalization of $2.71 billion, a price-to-earnings ratio of -721.00, a PEG ratio of 4.08 and a beta of 1.39.

GoodRx (NASDAQ:GDRX) last released its quarterly earnings data on Thursday, May 9th. The company reported $0.03 EPS for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.01). The firm had revenue of $197.88 million during the quarter, compared to analyst estimates of $196.20 million. GoodRx had a positive return on equity of 3.45% and a negative net margin of 0.86%. On average, equities analysts expect that GoodRx will post 0.17 EPS for the current fiscal year.

Institutional Investors Weigh In On GoodRx

Institutional investors have recently added to or reduced their stakes in the company. Beacon Capital Management LLC acquired a new position in shares of GoodRx in the 1st quarter valued at $28,000. Plato Investment Management Ltd acquired a new position in GoodRx in the second quarter worth about $43,000. Gerber LLC bought a new position in GoodRx during the fourth quarter worth about $75,000. Innealta Capital LLC acquired a new stake in GoodRx during the fourth quarter valued at approximately $91,000. Finally, Schnieders Capital Management LLC bought a new stake in shares of GoodRx in the 1st quarter valued at approximately $93,000. 63.77% of the stock is owned by institutional investors and hedge funds.

About GoodRx

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.